Herpes zoster and postherpetic neuralgia: Optimizing management in the elderly patient

Drugs and Aging

Volumn 25, Issue 12, 2008, Pages 991-1006

  Johnson, Robert W ^a,d   Wasner, Gunnar ^b   Saddier, Patricia ^c   Baron, Ralf ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF KIEL   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE   (United Kingdom)

Author keywords

Aciclovir, therapeutic use; Brivudine, therapeutic use; Capsaicin, therapeutic use; Elderly; Famciclovir, therapeutic use; Gabapentin, therapeutic use; Herpes zoster, treatment; Lidocaine, therapeutic use; Opioid analgesics, therapeutic use

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMITRIPTYLINE; CAPSAICIN; CORTICOSTEROID; DESIPRAMINE; DEXTROMETHORPHAN; FAMCICLOVIR; FLUOROURACIL; FLUOXETINE; FLUPHENAZINE; GABAPENTIN; LIDOCAINE; LOCAL ANESTHETIC AGENT; MAPROTILINE; METHYLPREDNISOLONE; MORPHINE; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PREGABALIN; TRAMADOL; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

AGING; AMNESIA; ATAXIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRAIN VASCULITIS; BURNING SENSATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; EVENING DOSAGE; EYE INJURY; GLAUCOMA; GUILLAIN BARRE SYNDROME; HEADACHE; HEALTH PROMOTION; HEART CONDUCTION; HEMOLYTIC UREMIC SYNDROME; HERPES ZOSTER; HUMAN; HYPERALGESIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PARESIS; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RASH; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPINAL CORD STIMULATION; SUDDEN DEATH; THROMBOCYTOPENIC PURPURA; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VARICELLA ZOSTER VIRUS; XEROSTOMIA;

AGED; CHICKENPOX; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; NEURALGIA, POSTHERPETIC;

EID: 56649103893     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200825120-00002     Document Type: Review

References (90)

1. de Melker H, Berbers G, Hahné S, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24 (18): 3946-52.
2. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70 Suppl. 1: S111-8.
3. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998; 3 (11): 886-90.
4. Mandal BK, Mukherjee PP, Murphy C, et al. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. J Infect Dis 1998; 178 Suppl. 1: S52-4.
5. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352: 2266-7
6. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84
7. Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70 Suppl. 1: S24-30
8. Attal N, Fermanian C, Fermanian J, et al. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008 Mar 4; 138 (2): 343-53
9. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25: 571-5
10. Yawn BP, Saddier P, Wallen PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-9
11. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003; 70 Suppl. 1: S9-14
12. Heymann AD, Chodick G, Karpati T, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008; 36 (3): 226-30
13. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9-20
14. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61: 310-6
15. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-9
16. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3: 335-42
17. Helgason S, Sigurdsson J, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996; 2: 12-5
18. Opstelten W, Van Essen GA, Schellevis F, et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006; 16 (9): 692-5
19. di Luzio Paparatti UD, Arpinelli F, Visona G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999; 38 (2): 116-9.
20. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33 (1): 62-9.
21. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. Epub 2008 May 9
22. Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002; 44: 211-9
23. Edmunds WJ, Brisson M, Gay NJ, et al. Varicella vaccination: a double-edged sword? Commun Dis Public Health 2002; 5: 185-6
24. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127 (2): 305-14.
25. Jung BF, Johnson RW, Griffin DRJ, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545-51
26. Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007; 7: 1581-95
27. Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24: 1308-14
28. MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 2003; 131: 675-82
29. Saddier P, Sy L, Nikas A, et al. Herpes zoster hospitalizations in the United States, 1998-2002 [poster]. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA); 2006 Oct 12-15; Toronto (ON)
30. Gil A, San-Martin M, Carrasco P, et al. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004; 22: 3947-51
31. Statistics Canada. Number of deaths attributed to zoster in Canada [online]. Available from URL: http://www.statcan.ca:8096/bsolc/english/bsolc? catno=84-208-XIE [Accessed 2005 Feb 9]
32. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-7
33. Wassilew S. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients: a randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005; 19: 47-55
34. Keam SJ, Chapman TM, Figgitt DP. Brivudin (bromovinyl deoxyuridine). Drugs 2004; 64: 2091-7
35. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl. 1: S1-26
36. Tyring S, Barbarash RA, Nahlik JE. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (2): 89-96
37. Jackson JL, Gibbons R, Meyer G, et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 1997; 157: 909-12
38. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract 2000; 49: 255-64
39. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900
40. Whitley RJ, Weiss H, Gnann J, et al. The efficacy of steroids and acyclovir therapy of herpes zoster in the elderly. Antiviral Res 1996; 20 (1): 67-8
41. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327-31
42. van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006; 367: 219-24
43. Higa K, Dan K, Manabe H, et al. Factors influencing the duration of treatment of acute herpetic pain with sympathetic nerve block: importance of severity of herpes zoster assessed by the maximum antibody titers to varicella-zoster virus in otherwise healthy patients. Pain 1988; 32: 147-57
44. Manabe H, Dan K, Higa K. Continuous epidural infusion of local anesthetics and shorter duration of acute zoster-associated pain. Clin J Pain 1995; 11: 220-8
45. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000; 87: 121-9
46. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2: 628-44
47. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 63: 959-65
48. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305
49. Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008; 9: S19-30
50. Johnson RW. Herpes zoster pain including shingles and postherpetic neuralgia. In: Rice A, Wilson P, Watson P, et al., editors. Textbook of clinical pain management: chronic pain volume. 2nd ed. London: Hodder Arnold, 2008: 429-39
51. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015-21
52. Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671-3
53. Max MB, Schafer SC, Culnane K. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427-32
54. Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. Pain 1992; 48: 29-36
55. Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51: 1166-71
56. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16: 188-92
57. Rowbotham MC, Reisner LA, Davies PS, et al. Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial. J Pain 2005; 6: 741-6
58. Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 234-41
59. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94: 215-24
60. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-42
61. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, place-controlled clinical trial. Pain 2004; 109: 26-35
62. Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60: 1274-83
63. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115: 254-63
64. Oaklander AL, Buchbinder BR. Pregabalin-withdrawal encephalopathy and splenial edema: a link to high-altitude illness? Ann Neurol 2005; 58: 309-12
65. Bowsher D. The management of postherpetic neuralgia. Postgrad Med J 1997; 73: 623-9
66. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003; 104: 323-31
67. Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003; 7: 381-6
68. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41: 1024-8
69. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837-41
70. Recommendations for the appropriate use of opioids in persistent non-cancer pain [online]. Available from URL: http://www.britishpainsociety.org/ book_opioid_main.pdf [Accessed 2008 Oct 7]
71. American Pain Society. Advocacy: the use of opioids for the treatment of chronic pain [online]. Available from URL: www.ampainsoc.org/advocacy/opioids. htm [Accessed 2008 Oct 7]
72. Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989; 21: 265-70
73. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993; 15: 510-26
74. Backonja M. High-concentration capsaicin for the treatment of PHN and HIV neuropathy pain [abstract]. Eur J Pain 2007; 11: S40
75. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999; 80: 533-8
76. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151-8
77. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996; 65: 39-44
78. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995; 37: 246-53
79. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methyl-prednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343: 1514-9
80. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48: 1212-8
81. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain 2000; 16: S101-5
82. Haythornthwaite JA, Clark MR, Pappagallo M, et al. Pain coping strategies play a role in the persistence of pain in postherpetic neuralgia. Pain 2003; 106: 453-60
83. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-34
84. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95: 434-41
85. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008; 122 (3): e744-51
86. Reynolds MA, Chaves SS, Harpaz R, et al. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008; 197 Suppl. 2: S224-7
87. Hardy I, Gershon AA, Steinberg SP, et al. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325: 1545-50
88. Gershon AA, LaRussa P, Steinberg S, et al. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996; 173: 450-3
89. Johnson R. Patient awareness of herpes zoster: the Global Herpes Zoster Survey: a preliminary report. Herpes 2006; 13 Suppl. 1: 40-1
90. Hurley LP, Harpaz R, Daley MF, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis 2008; 197 Suppl. 2: S216-23